These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 21833718)

  • 1. Targeting glucosylceramide synthase sensitizes imatinib-resistant chronic myeloid leukemia cells via endogenous ceramide accumulation.
    Baran Y; Bielawski J; Gunduz U; Ogretmen B
    J Cancer Res Clin Oncol; 2011 Oct; 137(10):1535-44. PubMed ID: 21833718
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alterations of ceramide/sphingosine 1-phosphate rheostat involved in the regulation of resistance to imatinib-induced apoptosis in K562 human chronic myeloid leukemia cells.
    Baran Y; Salas A; Senkal CE; Gunduz U; Bielawski J; Obeid LM; Ogretmen B
    J Biol Chem; 2007 Apr; 282(15):10922-34. PubMed ID: 17303574
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glucosylceramide synthase inhibitor PDMP sensitizes chronic myeloid leukemia T315I mutant to Bcr-Abl inhibitor and cooperatively induces glycogen synthase kinase-3-regulated apoptosis.
    Huang WC; Tsai CC; Chen CL; Chen TY; Chen YP; Lin YS; Lu PJ; Lin CM; Wang SH; Tsao CW; Wang CY; Cheng YL; Hsieh CY; Tseng PC; Lin CF
    FASEB J; 2011 Oct; 25(10):3661-73. PubMed ID: 21705667
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Silencing of suppressor of cytokine signaling-3 due to methylation results in phosphorylation of STAT3 in imatinib resistant BCR-ABL positive chronic myeloid leukemia cells.
    Al-Jamal HA; Jusoh SA; Yong AC; Asan JM; Hassan R; Johan MF
    Asian Pac J Cancer Prev; 2014; 15(11):4555-61. PubMed ID: 24969884
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Resveratrol triggers apoptosis through regulating ceramide metabolizing genes in human K562 chronic myeloid leukemia cells.
    Kartal M; Saydam G; Sahin F; Baran Y
    Nutr Cancer; 2011; 63(4):637-44. PubMed ID: 21500096
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The antiproliferation effect of berbamine on k562 resistant cells by inhibiting NF-kappaB pathway.
    Wei YL; Liang Y; Xu L; Zhao XY
    Anat Rec (Hoboken); 2009 Jul; 292(7):945-50. PubMed ID: 19548306
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Roles of ceramide synthase and ceramide clearence genes in nilotinib-induced cell death in chronic myeloid leukemia cells.
    Camgoz A; Gencer EB; Ural AU; Avcu F; Baran Y
    Leuk Lymphoma; 2011 Aug; 52(8):1574-84. PubMed ID: 21756066
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Berbamine exhibits potent antitumor effects on imatinib-resistant CML cells in vitro and in vivo.
    Wei YL; Xu L; Liang Y; Xu XH; Zhao XY
    Acta Pharmacol Sin; 2009 Apr; 30(4):451-7. PubMed ID: 19270722
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A molecular and biophysical comparison of macromolecular changes in imatinib-sensitive and imatinib-resistant K562 cells exposed to ponatinib.
    Yandim MK; Ceylan C; Elmas E; Baran Y
    Tumour Biol; 2016 Feb; 37(2):2365-78. PubMed ID: 26373734
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel mechanism of dasatinib-induced apoptosis in chronic myeloid leukemia; ceramide synthase and ceramide clearance genes.
    Gencer EB; Ural AU; Avcu F; Baran Y
    Ann Hematol; 2011 Nov; 90(11):1265-75. PubMed ID: 21455605
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Divalproex sodium enhances the anti-leukemic effects of imatinib in chronic myeloid leukemia cells partly through SIRT1.
    Wang W; Zhang J; Li Y; Yang X; He Y; Li T; Ren F; Zhang J; Lin R
    Cancer Lett; 2015 Jan; 356(2 Pt B):791-9. PubMed ID: 25449787
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabolic characteristics of imatinib resistance in chronic myeloid leukaemia cells.
    Klawitter J; Kominsky DJ; Brown JL; Klawitter J; Christians U; Leibfritz D; Melo JV; Eckhardt SG; Serkova NJ
    Br J Pharmacol; 2009 Sep; 158(2):588-600. PubMed ID: 19663881
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tetrandrine citrate eliminates imatinib-resistant chronic myeloid leukemia cells in vitro and in vivo by inhibiting Bcr-Abl/β-catenin axis.
    Xu XH; Gan YC; Xu GB; Chen T; Zhou H; Tang JF; Gu Y; Xu F; Xie YY; Zhao XY; Xu RZ
    J Zhejiang Univ Sci B; 2012 Nov; 13(11):867-74. PubMed ID: 23125079
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ceramide promotes apoptosis in chronic myelogenous leukemia-derived K562 cells by a mechanism involving caspase-8 and JNK.
    Nica AF; Tsao CC; Watt JC; Jiffar T; Kurinna S; Jurasz P; Konopleva M; Andreeff M; Radomski MW; Ruvolo PP
    Cell Cycle; 2008 Nov; 7(21):3362-70. PubMed ID: 18948750
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Growth inhibition and differentiation of imatinib-resistant chronic myeloid leukemia cell induced by cell differentiation agent in vitro].
    Wang XD; Qiu L; Lu RZ; Chen LJ; Zhan ZM; Han BH; Zhang BL; Ma J
    Zhonghua Yi Xue Za Zhi; 2007 Dec; 87(48):3399-405. PubMed ID: 18476538
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Apoptotic effects of resveratrol, a grape polyphenol, on imatinib-sensitive and resistant K562 chronic myeloid leukemia cells.
    Can G; Cakir Z; Kartal M; Gunduz U; Baran Y
    Anticancer Res; 2012 Jul; 32(7):2673-8. PubMed ID: 22753725
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro studies of the combination of imatinib mesylate (Gleevec) and arsenic trioxide (Trisenox) in chronic myelogenous leukemia.
    La Rosée P; Johnson K; O'Dwyer ME; Druker BJ
    Exp Hematol; 2002 Jul; 30(7):729-37. PubMed ID: 12135670
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanisms of cellular resistance to imatinib in human chronic myeloid leukemia cells.
    Baran Y; Ural AU; Gunduz U
    Hematology; 2007 Dec; 12(6):497-503. PubMed ID: 17852433
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Distinct interaction of nilotinib and imatinib with P-Glycoprotein in intracellular accumulation and cytotoxicity in CML Cell Line K562 cells.
    Yamakawa Y; Hamada A; Uchida T; Sato D; Yuki M; Hayashi M; Kawaguchi T; Saito H
    Biol Pharm Bull; 2014; 37(8):1330-5. PubMed ID: 25087954
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CUEDC2 sensitizes chronic myeloid leukemic cells to imatinib treatment.
    Zhang H; Chang G; Wang J; Lin Y; Ma L; Pang T
    Leuk Res; 2013 Nov; 37(11):1583-91. PubMed ID: 24125838
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.